Annual report [Section 13 and 15(d), not S-K Item 405]

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

12 Months Ended

Dec. 31, 2024

ROYALTY OBLIGATIONS NET

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(435,421	)		$	(1,731	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(105,372	)		$	(606	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(7,384	)		$	(5,113	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(1,787	)		$	(1,790	)

Schedule of changes in non-controlling interest

Balance, December 31, 2023		$	(128,834	)
Net loss attributable to the non-controlling interest			(105,978	)
Balance, December 31, 2024			(234,812	)

Balance, December 31, 2022		$	(125,257	)
Net loss attributable to the non-controlling interest			(3,577	)
Balance, December 31, 2023			(128,834	)